Abstract
Systemic and biological therapies are evolving treatment modalities in the management of atopic dermatitis (AD). Despite these welcome advances in the management of refractory cases, phototherapy remains the recommended1 second-line treatment option for AD when topical treatments fail to control symptoms. According to a recently published survey of UK dermatologists2, 46% of dermatologists still choose phototherapy, either narrow-band ultraviolet B (NB UVB) or psoralen ultraviolet A (PUVA) ahead of systemic therapy which is favoured by 36%. This article is protected by copyright. All rights reserved.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
